Radiation treatment for local pancreatic cancer recurrence
Part of Cancer clinical trials.
This trial looks at additional treatment using a special type of focused radiation (stereotactic body radiation therapy) for pancreatic cancer that has come back only in the same area after surgery. It may help by controlling the local recurrence and possibly improving outcomes for people whose cancer has not spread elsewhere.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already joined the PACAP study and signed consent to be randomized in future research
- Your pancreatic cancer must have come back only in the original area (local recurrence) after you had the pancreas surgery
- You must be 18 years or older
- Your cancer must NOT have spread to distant organs (no distant metastases)
- You should not have a short expected lifespan of less than 3 months
- You must be able to get scans like CT or MRI needed for the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a standardized plan for check-ups to detect pancreatic cancer returning after surgery. It may help find recurrence earlier and guide what follow-up care you might need next.
This trial tests a very focused type of radiation (SBRT) for people with pancreatic cancer that hasn't spread to other organs but can't be removed with surgery. It may be an option if you are medically unable to have surgery or choose not to.
This trial tests a new type of MRI-guided radiation therapy for people with locally advanced pancreatic cancer that can't be removed by surgery. If you have already had 2 months of chemotherapy, or chose not to, this treatment might help control the tumor.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
This trial tests if adding radiation and an immunotherapy drug (serplulimab) to standard chemotherapy can help people with pancreatic cancer that has come back or spread. It is for those who haven't had prior treatment for advanced disease.
This trial tests whether adding a focused radiation treatment (SBRT) to ongoing chemotherapy drugs works better than the drugs alone for pancreatic cancer that has stabilized or shrunk after initial treatment. The goal is to see if this combination approach helps patients live longer.
Hear when a new Recurrent Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.